Treatment for soft tissue sarcoma in childhood and adolescence

Modritz, D.; Ladenstein, Ruth; Pötschger, Ulrike; Amman, Gabriele; Dieckmann, Karin; Horcher, Ernst; Urban, C; Meister, Bernhard; Schimrigk, К.; Jones, Regina; Kaulfersch, W; Haas, Hans; Moser, Reinhard; Stöllinger, Olaf; Peham, Martina; Gadner, Helmut; Kościelniak, Ewa; Treuner, J.

doi:10.1007/s00508-004-5-0285-8

Cited by 42 publications

(35 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The major role of chemotherapy in this tumor location is the reduction of the primary tumor mass in order to assist with local therapy as well as to avoid tumor progression and the development of distant metastases [10].…”

Section: Discussionmentioning

confidence: 99%

“…Patients in the standard risk group received treatment with IVA (ifosfamide, vincristine, dactinomycin) and patients in the high-risk group were randomized to receive chemotherapy with VAIA (vincristine, ifosfamide, doxorubicin, dactinomycin) or CEVAIE (carboplatin, epirubicin, vincristine, dactinomycin, ifosfamide, etoposide). Neoadjuvant chemotherapy was prescribed for the majority of patients with macroscopic residual tumors after initial biopsy (IRS-Group III) [10]. In this group, radiological response was assessed after nine weeks using computed tomography (CT) or magnetic resonance imaging (MRI) as local treatment depended on the proportion of tumor volume reduction (Fig.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS‐96

Seitz¹,

Dantonello²,

Int-Veen³

et al. 2010

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

BackgroundTo analyze the clinical course, treatment modalities, complications and outcome of patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma (BPRMS) treated on the CWS‐96 trial.ProcedureThere were 85 patients with BPRMS enrolled and 63 patients with embryonal non‐metastatic BPRMS were analyzed. Fifty‐six patients received neoadjuvant chemotherapy and response was assessed radiographically after 9 weeks. Local therapy with radiation and or surgery was performed based on age, tumor size, and response. Patients were treated with adjuvant chemotherapy following local control.ResultsPatient's age ranged from 0 to 16 years with a median follow up of 5.3 years. Eighty nine percent of the patients had IRS group III disease. The 5‐year overall survival (OS) for the whole group was 76.3 ± 5.6% and the 5‐year event‐free survival (EFS) 69.8 ± 6.2%. Seventeen patients underwent preoperative radiochemotherapy followed by tumor resection (5‐year‐OS: 87.8 ± 8.1%). Eight patients were treated with solely radiochemotherapy (87.5 ± 11.7%). Twenty‐five patients received chemotherapy and tumor resection (OS: 83.6 ± 7.5%). Thirteen patients underwent incomplete tumor resection and were treated with radiochemotherapy postoperatively (OS: 39.9 ± 14.8%, P < 0.05 vs. other groups).ConclusionsLocal therapy is an important factor for prognosis of localized embryonal BPRMS. Inadequate primary or secondary surgery compromises the outcome and should be avoided. Radiotherapy alone, complete surgical tumor resection or combined preoperative radiotherapy with surgical resection lead to similar good local control rates and prognosis. Pediatr Blood Cancer 2011;56:718–724. © 2010 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS‐96

Seitz¹,

Dantonello²,

Int-Veen³

et al. 2010

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, and also in contrast to almost all pediatric tumors, multi-center prospective collaborative studies in which smaller centers can participate [30][31][32] do not yet exist for retinoblastoma [14]. A collaborative study on the benefits and toxicities of chemoreduction is presently under way in the USA, sponsored by the Children's Oncology Group [3].…”

Section: Focal Treatments Used With Chemoreductionmentioning

confidence: 99%

Retinoblastom: Vorschlag eines multimodalen Behandlungskonzeptes für Patienten mit intraokularem Retinoblastom in Österreich

Sovinz

Urban

Lackner

et al. 2006

Wien Klin Wochenschr

Self Cite

View full text Add to dashboard Cite

Retinoblastoma is the most common intraocular malignancy in childhood. If confined to the globe and managed with current treatment strategies, more than 90% of children survive with preservation of vision in at least one eye, even in bilateral retinoblastoma. Enucleation of the involved eye in unilateral retinoblastoma and of the more involved eye in bilateral disease, together with external beam radiotherapy in advanced bilateral retinoblastoma, formed the two cornerstones of treatment for many years and led to an increase in survival to over 90%. In the early 1990s the extent of the risk of second cancers in the field of radiation became known, the risk increasing by 10% per decade of life. As a consequence, chemotherapy-based regimens were developed as alternative treatments. During the past ten years retinoblastoma treatment has fundamentally changed, with a trend away from enucleation and external beam radiotherapy towards conservative treatments aiming at preservation of the affected globe(s) in selected patients. Systemic neoadjuvant chemotherapy induces tumor regression (chemoreduction), and residual regressed tumor is then treated focally with, for example, transpupillary thermotherapy, cryotherapy and plaque radiotherapy (consolidation). Between 1984 and 2004, 27 patients were treated at the department of ophthalmology in collaboration with the department of pediatrics at the Medical University of Graz. Before 2001, the affected eyes of all patients with unilateral retinoblastoma were enucleated (10 of 10), as were 6 of 7 of the more involved eyes of patients with bilateral disease. A globe-sparing strategy was introduced in 2001 and since then eligible patients have been treated with chemoreduction and focal therapy; 2 of 5 eyes with unilateral disease were salvaged, and both eyes of a patient with bilateral disease. We discuss current treatment options and present a proposal for the management of intraocular retinoblastoma in children in Austria, the Austrian retinoblastoma study, RB A-2003.

show abstract

“…Seit den 1970er Jahren werden pädiatrische Patienten mit malignen Erkrankungen praktisch ausschließlich innerhalb von prospektiven multizentrischen Studien (so genannten Therapieoptimierungsstudien) nach einheitlichen Therapierichtlinien behandelt [22][23][24]. Dies ermöglicht die Rekrutierung statistisch aussagekräftiger Patientenzahlen in einem überschaubaren Zeitraum von wenigen Jahren; einzelne Therapieelemente können so an genügend großen Patientengruppen randomisiert geprüft werden.…”

Section: Retinoblastom -Eine Interdisziplinäre Herausforderungunclassified

Retinoblastom – eine interdisziplinäre Herausforderung

Gadner¹

2006

Wien Klin Wochenschr

Self Cite

View full text Add to dashboard Cite

Treatment for soft tissue sarcoma in childhood and adolescence

Cited by 42 publications

References 27 publications

Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS‐96

Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS‐96

Retinoblastom: Vorschlag eines multimodalen Behandlungskonzeptes für Patienten mit intraokularem Retinoblastom in Österreich

Retinoblastom – eine interdisziplinäre Herausforderung

Contact Info

Product

Resources

About